Showing 7211-7220 of 8790 results for "".
- Cetaphil Sensitive Skin Awareness Month Kicks off on March 1, 2022https://practicaldermatology.com/news/cetaphil-sensitive-skin-awareness-month-kicks-off-on-march-1-2022/2461093/Cetaphil is extending Sensitive Skin Awareness Week to a month-long program. Cetaphil is debuting Sensitive Skin Awareness Month this March. In partnership with expert dermatologists and influencers – dubbed the Sensitive Skin Academy – Cetaphil 
- Business News: Taro to Acquire Alchemee From Galdermahttps://practicaldermatology.com/news/business-news-taro-to-acquire-alchemee-from-galderma/2461087/Taro Pharmaceutical Industries Ltd. Is buying Alchemee, formerly The Proactiv Company, from Galderma. The acquisition is subject to customary closing conditions and any necessary regulatory approvals. Financial terms of the transaction have not been disclosed. "We are exc
- Study Establishes Optimal Drug Delivery Settings for Needle-free Jet Injectorshttps://practicaldermatology.com/news/study-establishes-optimal-drug-delivery-settings-for-needle-free-jet-injectors/2461085/Needle-free jet injectors have been used in dermatological practice for many years for the nearly pain-free transdermal drug delivery for indications such as hypertrophic scars, keloids, and warts, but predefined clinical endpoints that guide physicians to choose optimal device settings have not
- Cyspera Launches New Three-Step System to Treat Hyperpigmentationhttps://practicaldermatology.com/news/cyspera-launches-new-three-step-system-to-treat-hyperpigmentation/2461083/Scientis is launching Cyspera Intensive System, a new three-product system designed to improve hyperpigmentation. Cysteamine inhibits several steps in the melanogenesis pathway while also working as antioxidant to protect against free radicals. The
- AbbVie, University of Toronto Establish Endowed Chair in Ethnodermatologyhttps://practicaldermatology.com/news/abbvie-university-of-toronto-establish-endowed-chair-in-ethnodermatology/2461081/AbbVie donated CDN $3M to establish an AbbVie Chair in Ethnodermatology at the University of Toronto’s Temerty Faculty of Medicine. One of the first positions of its kind in the world, the Chair will drive collaborative academic research, provide advanc
- Acne Breakthrough: Fat Cells in the Skin May Help Fight Acnehttps://practicaldermatology.com/news/fat-cells-in-the-skin-may-help-fight-acne/2461080/New research suggests that fibroblasts outside of hair follicles play a larger role in acne development. Fibroblasts produce an antimicrobial peptide called cathelicidin in skin. To counter an infection within a hair follicle, the surrounding skin undergoes a process called reactiv
- Third Harmonic Bio Launches with an Eye on Chronic Urticariahttps://practicaldermatology.com/news/third-harmonic-bio-launches-with-an-eye-on-chronic-urticaria/2461078/Third Harmonic Bio is launching with the close of a Series B financing campaign. With total capital to date of $155 million, the company plans to fund development of its lead candidate, THB001, through the next phase of human studies for the initial indication of chronic urticaria. 
- Study: Dermatologists Open to AIhttps://practicaldermatology.com/news/study-dermatologists-open-to-ai/2461075/Artificial intelligence (AI) may play a welcome role in dermatology, according to researchers from the George Washington University (GW) School of Medicine and Health Sciences (SMHS). AI, such as machine-learning, which has been incorporated into photography, dermoscopy, and confocal mi
- Study: Oral Dutasteride Outperforms Other Male Hair Loss Treatmentshttps://practicaldermatology.com/news/study-oral-dutasteride-outperforms-other-male-hair-loss-treatments/2461073/The top-ranking hair loss treatment for men is dutasteride (Avodart) capsules, at a dose of 0.5 milligrams a day, according to a new meta-analysis of 23 studies published online Feb. 2 in
- Solta Medical Files for IPOhttps://practicaldermatology.com/news/solta-medical-files-for-ipo/2461072/Bausch Subsidiary Solta Medical Corporation is getting ready to go public. The Company publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering ("IPO") of Solta's common shares.